Neuroendocrine tumor recurrence: Diagnosis with 68Ga-DOTATATE PET/CT

Radiology

Volumn 270, Issue 2, 2014, Pages 517-525

  Haug, Alexander R ^a   Cindea Drimus, Ramona ^a   Auernhammer, Christoph J ^a   Reincke, Martin ^a   Beuschlein, Felix ^a   Wängler, Björn ^a   Uebleis, Christopher ^a   Schmidt, Gerwin P ^a   Spitzweg, Christine ^a   Bartenstein, Peter ^a   Hacker, Marcus ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOISOTOPE; TETRAAZACYCLODODECANE TETRAACETIC ACID OCTREOTATE GA 68; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84893470896     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13122501     Document Type: Article

References (31)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008;26(18):3063- 3072.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13, 715 carcinoid tumors. Cancer 2003;97(4):934-959.
3. Boninsegna L, Panzuto F, Partelli S, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 2012;48(11):1608-1615.
4. Welin S, Stridsberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009;89(3):302-307.
5. Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012;95(2):135-156.
6. Arnold R, Chen YJ, Costa F, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009;90(2):227-233.
7. Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010;39(6):713-734.
8. Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012;95(2):120-134.
9. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90(2):167-183.
10. Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111) In-pentetreotide. Neuroendocrinology 2009;90(2):184-189.
11. Haug AR, Assmann G, Rist C, et al. Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT [in German]. Radiologe 2010;50(4):349-354.
12. Haug A, Auernhammer CJ, Wängler B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36(5):765-770.
13. Ruf J, Heuck F, Schiefer J, et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 2010;91(1):101-109.
14. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011;52(5):697-704.
15. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptormediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010;51(9):1349-1356.
16. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617-1626.
17. 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 2012;53(11):1686-1692.
18. Kumar R, Sharma P, Garg P, et al. Role of (68) Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 2011;21(11):2408-2416.
19. Naswa N, Sharma P, Kumar A, et al. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 2011;197(5):1221-1228.
20. 68Ga. Eur J Nucl Med Mol Imaging 2005;32(4):478-485.
21. Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga-DOTATATE and 18FFDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50(12):1927-1932.
22. Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTANOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37(10):2004-2010.
23. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 2012;56(1):40-47.
24. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008;6(7):820-827.
25. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A: biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17(9):2427-2443.
26. Frilling A, Sotiropoulos GC, Radtke A, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 2010;252(5):850-856.
27. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508-518.
28. Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50(8):1214-1221.
29. Narayanan P, Sohaib SA, Sahdev A, Rockall AG, Reznek RH. MR imaging of small adnexal masses [abstr]. Cancer Imaging 2010;10(A):S125.
30. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 2010;39(6):753-766.
31. Krausz Y, Rubinstein R, Appelbaum L, et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med 2012;37(1):57-62.